Anna Schmitt

Institut Bergonié — France

Medicine · Health Sciences

19h-index1.9kcitations73works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(31), CNS Lymphoma Diagnosis and Treatment(22), Multiple Myeloma Research and Treatments(15), Chronic Myeloid Leukemia Treatments(12), Glioma Diagnosis and Treatment(11)

Publications72 total

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)
Blood·2025
CTNI-59. ANALYSIS OF GENETIC MUTATION PROFILE AND CNS PHARMACOKINETICS IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA PATIENTS RESPONDING TO NOVEL EMAVUSERTIB (IRAK4I) AND BTKI COMBINATION
Neuro-Oncology·2025Open Access
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing
Blood·2025· 2 cited
Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI
Radiology Imaging Cancer·2025Open Access
160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL
Hematological Oncology·2025· 1 citedOpen Access
Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination.
Journal of Clinical Oncology·2025
Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study
Revue Neurologique·2024· 1 cited
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
Journal of Hematology & Oncology·2024Open Access
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica·2023· 3 citedOpen Access
Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.
Hematological Oncology·2023Open Access
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
Haematologica·2023· 15 citedOpen Access
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023Open Access
Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study
Annals of Hematology·2023· 3 cited
A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study
Journal of Medical Internet Research·2023· 15 citedOpen Access
Molecular and clinical diversity in primary central nervous system lymphoma
Annals of Oncology·2022· 77 citedOpen Access
What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
Blood·2022· 2 cited
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study
Journal of Clinical Oncology·2022· 89 cited
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study
Hematological Oncology·2022· 8 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Roch Houot(16), Caroline Houillier(15), Carole Soussain(15), Khê Hoang‐Xuan(15), Gandhi Damaj(14), Sylvain Choquet(14), Cécile Moluçon‐Chabrot(13), Adrien Chauchet(13), Franck Morschhauser(12), Hervé Ghesquières(12), Rémy Gressin(12), Adrian Tempescul(12), Olivier Chinot(11), Emmanuel Gyan(11), Guido Ahle(10), Vincent Delwail(9), Valérie Touitou(9), Luc Taillandier(8), Philippe Agapé(8), Olivier Casasnovas(8)